The Lupus Foundation of America has announced this year’s winners of the Gina M. Finzi Memorial Student Summer Fellowship Program, designed to support students working in lupus research. Each award, worth $4,000, includes mentorship by an experienced researcher in the field of lupus. Winners, all young scientists, are pursuing…
Kyverna Therapeutics is planning to launch a Phase 1/2 trial in Germany to test KYV-101, its investigational cell therapy for lupus nephritis, a lupus complication characterized by kidney damage. The study was approved by the Paul Ehrlich Institute (PEI), which is responsible for examining clinical trials of investigational…
The first patient has been enrolled in a Phase 1 clinical trial testing KYV-101, Kyverna Therapeutics’ candidate cell therapy for refractory lupus nephritis, a serious lupus complication characterized by kidney damage and inflammation. The open-label trial, which follows FDA’s green light in November, is actively recruiting nine to…
Gracell Biotechnologies announced the launch of a Phase 1 clinical trial in China testing GC012F, its experimental dual FastCAR T-cell therapy, for hard-to-treat systemic lupus erythematosus (SLE). The investigator-initiated trial (NCT05846347), underway at The First Affiliated Hospital of the Zhejiang University College of Medicine, is recruiting adults ages…
People with systemic lupus erythematosus (SLE) have a unique mix of bacteria on their tongue compared with healthy people, according to a Chinese study. Bacteria diversity correlated with disease activity, but also with recovery after treatment. The findings suggest oral bacteria “may be a therapeutic target for exploring new…
Adding Saphnelo (anifrolumab-fnia) to standard therapy in people with moderate to severe systemic lupus erythematosus (SLE) is linked to reaching a state of low disease activity faster and more frequently, according to an analysis of data from two Phase 3 clinical trials. This low disease activity state was sustained for…
Almost half of women with systemic lupus erythematosus (SLE) who underwent assisted reproductive therapy (ART) became pregnant, and 83.3% of them had a successful delivery, a large retrospective study shows. Only a small number of women experienced lupus flares, but ART was linked to a higher incidence of premature…
Women with systemic lupus erythematosus (SLE) whose disease went into remission right before becoming pregnant show better outcomes in the post-partum period, including a lower flare rate, according to a two-year follow up study. These findings highlight how “planned pregnancy counseling is fundamental when managing SLE patients,” the researchers wrote.
When given on top of standard therapy, zetomipzomib led to clinically significant reductions in urine protein levels, a marker of kidney impairment, in systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe form of lupus that causes kidney damage. That’s according to full data from the now…
The incidence of systemic lupus erythematosus (SLE) has increased in the U.S. the past four decades, a recent study shows. Study data also indicated the increased incidence seen during that time was significantly higher among racial and ethnic minority populations. “As the US population grows more diverse, we might continue…